Mariann Byerwalter joins Scipher Medicine’s Board of Advisors
Mariann Byerwalter Mariann Byerwalter joins Scipher Medicine’s Board of Advisors WALTHAM, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Scipher Medicine,...
Year: 2020
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Call to be held Wednesday, December 9, 2020, at 1:00 p.m. ESTWORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Mustang...
Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer
Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead...
Biotricity Prepares 510(k) FDA Filing for Biotres
Required lab testing complete for Biotres a novel holter patch productREDWOOD CITY, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Biotricity...
MannKind and MidCap Amend Credit Facility
$10 million funded immediately$25 million available upon TreT FDA approvalInterest-only period extended to September 2022WESTLAKE VILLAGE, Calif., Dec. 01, 2020...
Healthwise Honored With Six Digital Health Awards® in the Fall 2020 Competition
BOISE, Idaho, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Healthwise, a leader in evidence-based health education, technology, and services, announced today...
VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology
ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in AdultsZILXI demonstrated a favorable safety and tolerability profile for...
electroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders
BASKING RIDGE, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that...
Safe and Efficacious Treatment of Spondylolisthesis via MIS TLIF Approach with the FlareHawk® Expandable Cage
IJSS-published review finds that the novel biplanar expandable cage provides effective vertebral body slip or spondylolisthesis reduction and improvement in...
FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer
SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the retirement of K. Peony Yu,...
Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab
New objective response in colon cancer triggers trial expansionLEXINGTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN),...
Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020
New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndromeFull results from Phase 3 study...
Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...
Sensus Healthcare Announces Study Showing Single Low Dose of Superficial Radiation Therapy Prevents Keloid Recurrence Following Surgical Excision
Prospective study published in Journal of the American Academy of Dermatology BOCA RATON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sensus...
Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated...
AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer
VALENCIA, Calif, and MELBOURNE, Australia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine...
BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
• Application accepted under Priority Review designation• Application accepted into Real Time Oncology Review (RTOR) pilot program• This is BridgeBio’s second NDA...
Jushi Holdings Inc. Announces Listing of 10% Senior Secured Notes Due January 15, 2023 on the Canadian Securities Exchange
BOCA RATON, Fla., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCMKTS: JUSHF),...
VitalHub Subsidiary Transforming Systems Secured Contract with Bedfordshire, Luton & Milton Keynes ICS
TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce that...
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease
SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing...